The Mclean Hospital Corporation

The Mclean Hospital Corporation Research Management Division, doing business as Mclean Hospital, operates as a prime recipient on federal grants and a research services provider to the National Institutes of Health and other agencies, with a portfolio anchored in neuroscience, psychiatric, and substance abuse research conducted as a nonprofit teaching hospital affiliated with Harvard Medical School based in Belmont, Massachusetts.

Mclean Hospital holds 457 prime awards (84% of total) across 544 federal transactions spanning contracts and grants, with most activity concentrated in basic and applied research rather than commercial service delivery. The organization competes in full-and-open procurements without set-aside designations. Recent activity shows 48 awards in 2024 and 27 in 2025, with a recompete cliff of $729 thousand in combined potential value over the next twenty-four months. The top three customer agencies by award count are the National Institute of Mental Health (143 awards), the National Institute on Drug Abuse (71 awards, $90.9 million combined potential value), and the National Institute of Neurological Disorders and Stroke (17 awards). Mclean also holds a five-year Blanket Purchase Agreement with the Drug Enforcement Administration (ceiling $1,062,961.53 through April 2029) for specialized scientific expertise in monitoring and regulating controlled substances, benzodiazepines, and emerging drugs; three task orders have been issued to date, with the most recent $134,311.86 call for benzodiazepine testing.

Concrete capability work spans neuroscience research, psychiatric disorder investigation, and substance abuse treatment science. Representative prime awards include a $34.494 million definitive contract with the National Institute on Drug Abuse (awarded November 2025, completing October 2030) to establish and operate a collection site of the NIH NeuroBank Brain and Tissue Repository, involving acquisition, processing, storage, curation, preservation, and distribution of central nervous system tissue and related materials to support neurological and psychiatric research. A $2.692 million NIDA definitive contract (awarded December 2023, completing December 2025) funded assessment of potential substance abuse treatment medications in nonhuman primate models. A $3.374 million National Center for Complementary and Integrative Health research grant (awarded July 2026, completing June 2029 under CFDA 93.213) investigates mechanisms and clinical impact of a high-CBD cannabinoid product on gynecologic pain through pharmacokinetic and inflammatory marker studies. Mclean also received a $34.494 million NIDA award for the NIH NeuroBank Brain and Tissue Repository collection site and multiple grants from the National Institute of Mental Health spanning synaptic function, major depressive disorder treatment mechanisms via transcranial magnetic stimulation, trauma recovery via EEG and actigraphy tracking, and quality-of-life measurement frameworks. DEA BPA calls awarded in 2024–2026 ($114,422 to $144,496 each) covered benzodiazepine and depressants testing services.

Mclean's federal grant portfolio encompasses CFDA programs including Mental Health Research Grants (NIMH, CFDA 93.242), Drug Use and Addiction Research Programs (NIDA, CFDA 93.279), and Research and Training in Complementary and Integrative Health (NCCIH, CFDA 93.213). Recent grant work includes K23 mentored career development awards supporting independent investigator training in substance use disorder and PTSD mechanistic clinical trials, and multiple R01 and R21 awards investigating neurobiology of psychiatric symptomatology, resilience, trauma exposure, and opioid use disorder treatment outcomes. Mclean acts as prime recipient on the majority of awards; it also serves as sub-recipient on collaborative grants led by institutions including Harvard College, the University of North Carolina at Chapel Hill, the Children's Hospital of Philadelphia, Brigham and Women's Hospital, and Yale University, typically contributing specialized neuroimaging expertise, clinical assessment capability, or biospecimen processing.

Service Contract Inventory data shows SCI-reportable invoiced revenue of $11.9 million across FY2022–FY2024 (FY2025 reflects zero invoicing to date). The FTE trajectory showed 16.9 FTEs in FY2022 declining to 12.0 FTEs in FY2024, all delivered as prime service hours with no named subcontractor engagement in SCI records. Government-paid hourly rates on prime service contracts ranged from a 10th percentile of $98.90/hr to a median of $130.64/hr and a 90th percentile of $138.70/hr, reflecting research and clinical specialist labor. Mclean performs work primarily at its Belmont, Massachusetts location; some awards specify performance at collaborating institutions or regional clinical sites.

Mclean Hospital is a child entity within Partners Healthcare System Incorporated. The organization's federal footprint reflects its institutional identity as a psychiatric teaching hospital with deep research infrastructure in neuroimaging (including a 9.4-Tesla preclinical MR system), biospecimen curation, clinical trial capability across psychiatric and substance use populations, and long-term relationships with NIH institutes and federal agencies conducting neuroscience and mental health research.